Markets:

Overview

News

Currencies

International

Treasuries

iShares U.S. Pharmaceutical ETF (NY:IHE)

86.78 -0.08 (-0.09%)

Streaming Delayed Price Updated: 3:11 PM EDT, Apr 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Pharmaceutical ETF

< Previous 1 2 3 Next >

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗

April 18, 2025

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Via Benzinga

Topics ETFs

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? ↗

April 03, 2025

Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.

Via Benzinga

Topics World Trade

3 Sector ETFs That Beat The Market Last Week ↗

August 14, 2023

Here are three ETFs from different sectors that were in green last week.

Via Talk Markets

Topics ETFs

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.

Via Benzinga

Topics ETFs Government World Trade

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗

February 17, 2025

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.

Via Benzinga

US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget ↗

February 11, 2025

A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21.

Via Benzinga

Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery ↗

January 24, 2025

Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely.

Via Benzinga

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗

December 19, 2024

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Via Benzinga

Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗

December 13, 2024

Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase.

Via Benzinga

Topics ETFs

FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen' ↗

November 13, 2024

FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency.

Via Benzinga

Topics Government

Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr. ↗

November 06, 2024

Robert Kennedy Jr. revealed Trump's directive to tackle health agency corruption, promote science, and end chronic disease.

Via Benzinga

Topics Government

A Look At Pharma ETFs Post Q1 Earnings ↗

May 07, 2024

Pharma ETFs have delivered mixed performances over the past month.

Via Talk Markets

Topics ETFs

ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook ↗

May 01, 2024

Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest...

Via Talk Markets

Topics ETFs

Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors ↗

February 26, 2024

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.

Via Benzinga

April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market ↗

April 30, 2024

Performance in April 2024: Utilities lead, real estate lags. S&P 500, Nasdaq 100, Dow Jones Industrial Average, small-cap and large-cap indices all decline.

Via Benzinga

Topics Stocks

A Look At Pharma ETFs After Q4 Earnings ↗

February 12, 2024

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.

Via Talk Markets

Topics ETFs

Bank Of America Predicts 10 2024 Market Surprises: From Booming IPOs To Japanese Equity Surge ↗

January 09, 2024

Bank of America lists 10 market surprises; warns investors to be wary of the bond market's dovish position compared to the Fed.

Via Benzinga

Topics Bonds

3 Beaten-Down ETFs To Buy For A Turnaround In 2024 ↗

December 22, 2023

Following three consecutive monthly losses since the COVID pandemic began in March 2020, Wall Street recorded a robust recovery starting in November. we have highlighted ETFs from different zones that...

Via Talk Markets

Topics ETFs

5 Secret Santa ETFs That Might Surprise You This Christmas ↗

December 16, 2023

Wall Street has been sizzling hot this holiday season. This is likely to continue, given that the Santa Claus rally is on the way. Against such a backdrop, there are some hidden gems which could...

Via Talk Markets

Topics ETFs

Pharmacy Workers Strike At CVS and Walgreens, Echoing Wider Pharma Sector Unrest ↗

November 05, 2023

In a recent surge of labor unrest, pharmacy employees from CVS Health Corporation (NYSE: CVS) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) raised their voices by calling out sick or walking out...

Via Benzinga

5 Sector ETFs That Outperformed in Turbulent August ↗

August 30, 2023

Wall Street has lost momentum since the start of August, triggered by the series of bank downgrades and fears of higher rates for a longer-than-expected period.

Via Talk Markets

Topics ETFs

Q2 Earnings & Market Sell-Off Impact: 5 Must-See ETF Charts ↗

August 25, 2023

While longer-than-expected rate worries and banking concerns led to feeble trading in recent weeks, a few equity ETFs rose or saw a modest decline over the past month.

Via Talk Markets

Topics ETFs

Pharma ETFs in Focus Post Q2 Earnings ↗

August 11, 2023

Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.

Via Talk Markets

Topics ETFs

3 Biotech Stocks to Sell in June Before They Crash and Burn ↗

June 06, 2023

Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them.

Via InvestorPlace

Pharma ETFs Gain Post Q1 Earnings ↗

May 09, 2023

Pharma ETFs have been in the green over the past month.

Via Talk Markets

A Look At Pharma ETFs Post Q4 Earnings ↗

February 08, 2023

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

4 Sector ETFs To Watch Ahead Of Mid-Election Results ↗

November 10, 2022

Some market analysts are signaling that a political gridlock by Republicans may be a positive for Wall Street and the U.S. economy.

Via Talk Markets

5 ETFs To Watch After 2022 Midterm Elections: Which Sectors Win From Republican Or Democrat Majority? ↗

November 09, 2022

The 2022 election was held on Tuesday, Nov. 8. No decision has been made as to who won many of the key battles, including several pivotal seats in the U.S. House of Representatives and U.S. Senate.

Via Benzinga

Pharma ETFs In Focus Post Q3 Earnings ↗

November 09, 2022

Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.